Trial Profile

LOWER: Lomitapide Observational Worldwide Evaluation Registry

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lomitapide (Primary)
Indications Hyperlipoproteinaemia type IIa
Focus Adverse reactions
Acronyms LOWER
Sponsors Aegerion Pharmaceuticals; Amryt Pharma

Most Recent Events

12 May 2026 Status changed from recruiting to completed.
01 Feb 2023 Results assessing long-term hepatic safety of lomitapide from phase III clinical studies and extension study: NCT00730236, NCT00943306 and NCT02135705 published in the Liver International
30 Mar 2020 Results (n=187; as of 1 Mar 2019) presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com